Realization of a label-free electrochemical immunosensor for detection of low density lipoprotein using NiO thin film

A novel electrochemical aptasensor based on NrGO-H-Mn3O4 NPs integrated CRISPR/Cas12a system for ultrasensitive low-density lipoprotein determination

Atherosclerosis cardiovascular disease (ASCVD) has become one of the leading death causes in humans. Low-density lipoprotein (LDL) is an important biomarker for assessing ASCVD risk level. Thus, monitoring LDL levels can be an important means for early diagnosis of ASCVD. Herein, a novel electrochemical aptasensor for determination LDL was designed based on nitrogen-doped reduced graphene oxide-hemin-manganese oxide nanoparticles (NrGO-H-Mn3O4 NPs) integrated with clustered regularly interspaced short palindromic repeats and associated proteins (CRISPR/Cas12a) system. NrGO-H-Mn3O4 NPs not only have a large surface area and remarkable enhanced electrical conductivity but also the interconversion of different valence states of iron in hemin can provide an electrical signal. Nonspecific single-stranded DNA (ssDNA) was bound to NrGO-H-Mn3O4 NPs to form a signaling probe and was immobilized on the electrode surface. The CRISPR/Cas12a system has excellent trans-cleavage activity, which can be used to cleave ssDNA, thus detaching the NrGO-H-Mn3O4 NPs from the sensing interface and attenuating the electrical signal. Significant signal change triggered by the target was ultimately obtained, thus achieving sensitive detection of the LDL in range from 0.005 to 1000.0 nM with the detection limit of 0.005 nM. The proposed sensor exhibited good stability, selectivity, and stability and achieved reliable detection of LDL in serum samples, demonstrating its promising application prospects for the diagnostic application of LDL.

Dual-mode biosensor platform based on synergistic effects of dual-functional hybrid nanomaterials

Detection of biomarkers is very vital in the prevention, diagnosis and treatment of diseases. However, due to the poor accuracy and sensitivity of the constructed biosensors, we are now facing great challenges. In addressing these problems, nanohybrid-based dual mode biosensors including optical-optical, optical-electrochemical and electrochemical-electrochemical have been developed to detect various biomarkers. Integrating the merits of nanomaterials with abundant active sites, synergy and excellent physicochemical properties, many bi-functional nanohybrids have been reasonable designed and controllable preparation, which applied to the construction dual mode biosensors. Despite the significant progress, further efforts are still needed to develop dual mode biosensors and ensure their practical application by using portable digital devices. Therefore, the present review summarizes an in-depth evaluation of the bi-functional nanohybrids assisted dual mode biosensing platform of biomarkers. We are hoping this review could inspire further concepts in developing novel dual mode biosensors for possible detection application.

Simultaneous Electrochemical Detection of LDL and MDA-LDL Using Antibody-Ferrocene or Anthraquinone Conjugates Coated Magnetic Beads

The simultaneous detection of atherosclerotic cardiovascular disease (ACSVD) biomarkers was recently of great scientific interest. In this work, magnetic beads-based immunosensors for the simultaneous detection of low density lipoprotein (LDL) and malondialdehyde-modified low density lipoprotein (MDA-LDL) were presented. The approach proposed was based on the formation of two types of specific immunoconjugates consisting of monoclonal antibodies: anti-LDL or anti-MDA-LDL, together with redox active molecules: ferrocene and anthraquinone, respectively, coated on magnetic beads (MBs). The decrease in redox agent current in the concentration range: 0.001-1.0 ng/mL for LDL and 0.01-10.0 ng/mL for MDA-LDL, registered by square wave voltammetry (SWV), was observed upon the creation of complex between LDL or MDA-LDL and appropriate immunoconjugates. The detection limits of 0.2 ng/mL for LDL and 0.1 ng/mL for MDA-LDL were estimated. Moreover, the results of selectivity against the possible interferents were good, as human serum albumin (HSA) and high density lipoprotein (HDL), stability and recovery studies demonstrated the potential of platform proposed for early prognosis and diagnosis of ASCVD.

Electrochemical approaches based on micro- and nanomaterials for diagnosing oxidative stress

This review article comprehensively discusses the various electrochemical approaches for measuring and detecting oxidative stress biomarkers and enzymes, particularly reactive oxygen/nitrogen species, highly reactive chemical molecules, which are the byproducts of normal aerobic metabolism and can oxidize cellular components such as DNA, lipids, and proteins. First, we address the latest research on the electrochemical determination of reactive oxygen species generating enzymes, followed by detection of oxidative stress biomarkers, and final determination of total antioxidant activity (endogenous and exogenous). Most electrochemical sensing platforms exploited the unique properties of micro- and nanomaterials such as carbon nanomaterials, metal or metal oxide nanoparticles (NPs), conductive polymers and metal-nano compounds, which have been mainly used for enhancing the electrocatalytic response of sensors/biosensors. The performance of the electroanalytical devices commonly measured by cyclic voltammetry (CV) and differential pulse voltammetry (DPV) in terms of detection limit, sensitivity, and linear range of detection is also discussed. This article provides a comprehensive review of electrode fabrication, characterization and evaluation of their performances, which are assisting to design and manufacture an appropriate electrochemical (bio)sensor for medical and clinical applications. The key points such as accessibility, affordability, rapidity, low cost, and high sensitivity of the electrochemical sensing devices are also highlighted for the diagnosis of oxidative stress. Overall, this review brings a timely discussion on past and current approaches for developing electrochemical sensors and biosensors mainly based on micro and nanomaterials for the diagnosis of oxidative stress.

Electrochemical devices for cholesterol detection

Cholesterol can be considered as a biomarker of illnesses such as heart and coronary artery diseases or arteriosclerosis. Therefore, the fast determination of its concentration in blood is interesting as a means of achieving an early diagnosis of these unhealthy conditions. Electrochemical sensors and biosensors have become a potential tool for selective and sensitive detection of this biomolecule, combining the analytical advantages of electrochemical techniques with the selective recognition features of modified electrodes. This review covers the different approaches carried out in the development of electrochemical sensors for cholesterol, differentiating between enzymatic biosensors and non-enzymatic systems, highlighting lab-on-a-chip devices. A description of the different modification procedures of the working electrode has been included and the role of the different functional materials used has been discussed.

The emergence of psychoanalytical electrochemistry: the translation of MDD biomarker discovery to diagnosis with electrochemical sensing

The disease burden and healthcare costs of psychiatric diseases along with the pursuit to understand their underlying biochemical mechanisms have led to psychiatric biomarker investigations. Current advances in evaluating candidate biomarkers for psychiatric diseases, such as major depressive disorder (MDD), focus on determining a specific biomarker signature or profile. The origins of candidate biomarkers are heterogenous, ranging from genomics, proteomics, and metabolomics, while incorporating associations with clinical characterization. Prior to clinical use, candidate biomarkers must be validated by large multi-site clinical studies, which can be used to determine the ideal MDD biomarker signature. Therefore, identifying valid biomarkers has been challenging, suggesting the need for alternative approaches. Following validation studies, new technology must be employed to transition from biomarker discovery to diagnostic biomolecular profiling. Current technologies used in discovery and validation, such as mass spectroscopy, are currently limited to clinical research due to the cost or complexity of equipment, sample preparation, or measurement analysis. Thus, other technologies such as electrochemical detection must be considered for point-of-care (POC) testing with the needed characteristics for physicians' offices. This review evaluates the advantages of using electrochemical sensing as a primary diagnostic platform due to its rapidity, accuracy, low cost, biomolecular detection diversity, multiplexed capacity, and instrument flexibility. We evaluate the capabilities of electrochemical methods in evaluating current candidate MDD biomarkers, individually and through multiplexed sensing, for promising applications in detecting MDD biosignatures in the POC setting.

Electrochemical sensor based on micromotor technology for detection of Ox-LDL in whole blood

Detecting the concentration of oxidized low-density lipoprotein (Ox-LDL) in whole blood is of great significance for monitoring the development of atherosclerosis. In order to simplify the complex processing steps of blood sample before the detection, an electrochemical sensor based on micromotor technology was designed, which was called magnesium (Mg)-Fe₃O₄@ prussian blue (PB)@ antibody of Ox-LDL (Ab)@ bovine serum albumin (BSA). The active capture of Ox-LDL in whole blood can be realized by the help of the movement of Mg microsphere with the driving force of H₂. Then the captured Ox-LDL was collected on the surface of the magnetic glassy carbon electrode (MGCE) by self-made funnel device, and the content of Ox-LDL was detected by electrochemical workstation in the way of chronoamperometry (i-t). Due to the application of micromotor, the electrochemical sensor proposed in this study had good detection efficiency for Ox-LDL in whole blood with range from 1 × 10^-2 μg/mL to 10 μg/mL, and the limit of detection (LOD) towards Ox-LDL was 9.80 × 10^-4 μg/mL. The electrochemical sensor based on micromotor technology provides a rapid, effective, and sensitive method for the detection of Ox-LDL in whole blood.

Antibody–Ferrocene Conjugates as a Platform for Electro-Chemical Detection of Low-Density Lipoprotein

Low-density lipoprotein (LDL) is a cardiac biomarker identified in the pathology of cardiovascular disease (CVD). Typically, the level of LDL is calculated using the Friedewald relationship based on measured values of total cholesterol, high-density lipoproteins (HDL), and triglycerides. Unfortunately, this approach leads to some errors in calculation. Therefore, direct methods that can be used for fast and accurate detection of LDL are needed. The purpose of this study was to develop an electrochemical platform for the detection of LDL based on an antibody–ferrocene conjugate. An anti-apolipoprotein B-100 antibody labeled with ferrocene was covalently immobilized on the layer of 4-aminothiophenol (4-ATP) on the surface of gold electrodes. Upon interaction between LDL and the antibody–ferrocene conjugate, a decrease in the ferrocene redox signal registered by square wave voltammetry was observed, which depends linearly on the concentration from 0.01 ng/mL to 1.0 ng/mL. The obtained limit of detection was equal to 0.53 ng/mL. Moreover, the satisfied selectivity toward human serum albumin (HSA), HDL, and malondialdehyde-modified low-density lipoprotein (MDA-LDL) was observed. In addition, the acceptable recovery rates of LDL in human serum samples indicate the possible application of immunosensors presented in clinical diagnostics.

Detection of Low Density Lipoprotein-Comparison of Electrochemical Immuno- and Aptasensor

An elevated level of low density lipoprotein (LDL) can lead to the cardiovascular system-related diseases, such as atherosclerosis and others. Therefore, fast, simple, and accurate methods for LDL detection are very desirable. In this work, the parameters characterizing the electrochemical immuno-and aptasensor for detection of LDL have been compared for the first time. An immunosensor has been designed, for which the anti-apolipoprotein B-100 antibody was covalently attached to 4-aminothiophenol (4-ATP) on the surface of the gold electrode. In the case of an aptasensor, the gold electrode was modified in a mixture of ssDNA aptamer specific for LDL modified with –SH group and 6-mercaptohexanol. Square-wave voltammetry has been used for detection of LDL in PBS containing redox active marker, [Fe(CN)₆]^3−/4−. Our results show the linear dependence of [Fe(CN)₆]^3−/4− redox signal changes on LDL concentration for both biosensors, in the range from 0.01 ng/mL to 1.0 ng/mL. The limit of detection was 0.31 and 0.25 ng/mL, for immuno- and aptasensor, respectively. Whereas slightly better selectivity toward human serum albumin (HSA), high density lipoprotein (HDL), and malondialdehyde modified low density lipoprotein (MDA-LDL) has been observed for aptasensor. Moreover, the other components of human blood serum samples did not influence aptasensor sensitivity.

Selective Molecular Recognition of Low Density Lipoprotein Based on β-Cyclodextrin Coated Electrochemical Biosensor

The excess of low-density lipoprotein (LDL) strongly promotes the accumulation of cholesterol on the arterial wall, which can easily lead to the atherosclerotic cardiovascular diseases (ACDs). It is a challenge on how to recognize and quantify the LDL with a simple and sensitive analytical technology. Herein, β-cyclodextrins (β-CDs), acting as molecular receptors, can bind with LDL to form stable inclusion complexes via the multiple interactions, including electrostatic, van der Waals forces, hydrogen bonding and hydrophobic interactions. With the combination of gold nanoparticles (Au NPs) and β-CDs, we developed an electrochemical sensor providing an excellent molecular recognition and sensing performance towards LDL detection. The LDL dynamic adsorption behavior on the surface of the β-CD-Au electrode was explored by electrochemical impedance spectroscopy (EIS), displaying that the electron-transfer resistance (Ret) values were proportional to the LDL (positively charged apolipoprotein B-100) concentrations. The β-CD-Au modified sensor exhibited a high selectivity and sensitivity (978 kΩ·µM⁻¹) toward LDL, especially in ultra-low concentrations compared with the common interferers HDL and HSA. Due to its excellent molecular recognition performance, β-CD-Au can be used as a sensing material to monitor LDL in human blood for preventing ACDs in the future.

Nanomaterial-based biosensors for measurement of lipids and lipoproteins towards point-of-care of cardiovascular disease

Cardiovascular disease (CVD) has become the primary cause of global deaths and inflicts an enormous healthcare burden on both developed and developing countries. Frequent monitoring of CVD-associated risk factors such as the level of lipids (e.g., triglyceride (TG) and total cholesterol (TC)) and lipoproteins (e.g., low-density lipoprotein (LDL) and high-density lipoprotein (HDL)) can effectively help prevent disease progression and improve clinical outcomes. However, measurement of these risk factors is generally integrated into an automated analyzer, which is prohibitively expensive and highly instrument-dependent for routine testing in primary care settings. As such, a variety of rapid, simple and portable nanomaterial-based biosensors have been developed for measuring the level of lipids (TG and TC) and lipoproteins (LDL and HDL) towards the management of CVD at the point-of-care (POC). In this review, we first summarize traditional methods for measurement of lipids and lipoproteins, and then present the latest advances in developing nanomaterial-based biosensors that can potentially monitor the risk factors of CVD at the POC.

Recent advances in designing nanomaterial based biointerfaces for electrochemical biosensing cardiovascular biomarkers

Early diagnosis of cardiovascular disease (CVD) is critically important for successful treatment and recovery of patients. At present, detection of CVD at early stages of its progression becomes a major issue for world health. The nanoscale electrochemical biosensors exhibit diverse outstanding properties, rendering them extremely suitable for the determination of CVD biomarkers at very low concentrations in biological fluids. The unique advantages offered by electrochemical biosensors in terms of sensitivity and stability imparted by nanostructuring the electrode surface together with high affinity and selectivity of bioreceptors have led to the development of new electrochemical biosensing strategies that have introduced as interesting alternatives to conventional methodologies for clinical diagnostics of CVD. This review provides an updated overview of selected examples during the period 2005-2018 involving electrochemical biosensing approaches and signal amplification strategies based on nanomaterials, which have been applied for determination of CVD biomarkers. The studied CVD biomarkers include AXL receptor tyrosine kinase, apolipoproteins, cholesterol, C-reactive protein (CRP), D-dimer, fibrinogen (Fib), glucose, insulin, interleukins, lipoproteins, myoglobin, N-terminal pro-B-type natriuretic peptide (BNP), tumor necrosis factor alpha (TNF-α) and troponins (Tns) on electrochemical transduction format. Identification of new specific CVD biomarkers, multiplex bioassay for the simultaneous determination of biomarkers, emergence of microfluidic biosensors, real-time analysis of biomarkers and point of care validation with high sensitivity and selectivity are the major challenges for future research.

Facile synthesis of cuprous oxide nanowires decorated graphene oxide nanosheets nanocomposites and its application in label-free electrochemical immunosensor

In this work, the assembly between one-dimensional (1D) nanomaterials and two-dimensional (2D) nanomaterials was achieved by a simple method. Cuprous oxide nanowires decorated graphene oxide nanosheets (Cu₂O@GO) nanocomposites were synthesized for the first time by a simple electrostatic self-assembly process. The nanostructure was well confirmed by scanning electron microscope (SEM) and transmission electron microscope (TEM) images. Taking advantages of good electrocatalytic activity and high specific surface area of Cu₂O@GO nanocomposites, a label-free electrochemical immunosensor was developed by employing Cu₂O@GO as signal amplification platform for the quantitative detection of alpha fetoprotein (AFP). In addition, toluidine blue (TB) was used as the electron transfer mediator to provide the electrochemical signal, which was adsorbed on graphene oxide nanosheets (GO NSs) by electrostatic attraction. The detection mechanism was based on the monitoring of the electrochemical current response change of TB by the square wave voltammetry (SWV) when immunoreaction occurred on the surface of electrode. Under optimal conditions, the proposed immunosensor displayed a high sensitivity and a low detection limit. This designed method may provide an effective method in the clinical diagnosis of AFP and other tumor markers.